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 Abstract 
The threat of West Nile virus (WNV) epidemics with increasingly severe neuroinvasive infections 
demands the development and licensing of effective vaccines. To date, vaccine candidates 
based on inactivated, live-attenuated, or chimeric virus, and viral DNA and WNV protein 
subunits have been developed. Some have been approved for veterinary use or are under 
clinical investigation, yet no vaccine has been licensed for human use. Reaching the milestone 
of a commercialized human vaccine, however, may largely depend on the economics of vaccine 
production. Analysis suggests that currently only novel low-cost production technologies would 
allow vaccination to outcompete the cost of surveillance and clinical treatment. Here, we review 
progress using plants to address the economic challenges of WNV vaccine production. The 
advantages of plants as hosts for vaccine production in cost, speed and scalability, especially 
those of viral vector-based transient expression systems, are discussed. The progress in 
developing WNV subunit vaccines in plants is reviewed within the context of their expression, 
characterization, downstream processing, and immunogenicity in animal models. The 
development of vaccines based on enveloped and non-enveloped virus-like particles was also 
discussed. These advancements suggest that plants may provide a production platform that 
offers potent, safe and affordable human vaccines against WNV.  
   
  
1 Introduction 
West Nile virus (WNV) is a mosquito-borne flavivirus in the Flaviviridae family closely related to 
the Japanese encephalitis (JEV), Kunjin (KUN), St Louis encephalitis, Murray Valley 
encephalitis, Dengue (DENV), yellow fever (YFV), and tick borne encephalitis viruses [1]. WNV 
has a single-stranded positive sense RNA genome of approximately 11 kilobases, which 
contains a single open reading frame (ORF) flanked by 5’ and 3’ non-coding regions [1].  The 
translation of the ORF produces a single polyprotein, which is processed into three structural 
proteins (capsid (CP), premembrane (prM), and envelope (E)) and seven nonstructural proteins 
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [2]. The translation of NS induces the 
formation of complex three-dimensional networks of membranes in which the replication of viral 
RNA occurs [3]. This leads to the production of negative sense RNA copies of the genome, 
each of which serves as a template for the replication of multiple copies of positive sense 
genomes. Each nascent genome either serves as a template for additional polyprotein 
translation or binds multiple copies of CP to form a nucleocapsid [3]. The nucleocapsid then 
buds into the lumen of the endoplasmic reticulum (ER), where E and prM proteins are anchored 
to form the immature virions. Cleavage of the N-terminal peptide of prM by cellular furin during 
the maturation pathway releases matured virions containing membrane (M) proteins from the 
cell though exocytosis [4]. As a result, the mature WNV is an enveloped virus of approximately 
50 nm in diameter with the nucleocapsid surrounded in a host ER-derived membrane that has 
been modified by the insertion of E and M proteins [4].   
For WNV, five distinct lineages have been described [5]. Lineage 1 includes strains that can 
cause neuroinvasive diseases in animals and humans, and have a world-wide distribution  
associated with epidemics in North America, Europe and Middle East [6]. Lineage 2 strains can 
also cause neuroinvasive infections and have recently spread from southern Africa into 
southern and central Europe [7]. Lineage 3 and 4 were identified in the Czech Republic and 
Russia, respectively, with each represented by a single isolate [8]. Lineage 5 strains have only 
been found in India and have not been documented to cause neuroinvasive infections [8]. WNV 
infection in humans causes a wide range of clinical manifestations, from mild fevers to fatal 
neuroinvasive diseases. Up to 80% of infected individuals may display no clinical symptoms or 
have mild symptoms of fever, headache, body ache, fatigue and skin rash [1]. In North America, 
approximately 1% of people infected develop severe neuroinvasive encephalitis, meningitis or 
poliomyelitis with acute flaccid paralysis [1]. The fatality rate of WNV neuroinvasive infections is 
approximately 10%, which increases dramatically with age and in immunocompromised 
individuals [1].  
In addition to humans, WNV also infect mosquitoes, ticks, birds, and other mammals [1]. Culex 
mosquitoes are primarily responsible for the transmission of WNV from wild birds - its main 
reservoir to humans and other mammals, which are dead-end hosts [1]. Migrating birds are 
primarily responsible for the global transmission of WNV [1] In addition to mosquitos, cases of 
WNV infection have also been reported as a result of blood transfusion, organ transplantation, 
breastfeeding and intra-uterine exposure [9].  
Historically, WNV was an Old World disease found mostly in the Eastern Europe, Africa, and the 
Middle East.  However, in 1999, WNV entered the American continent and subsequently spread 
across the United States (US), Canada, Caribbean, and Latin America, with outbreaks occurring 
on an annual basis [1]. In the US, the frequency and severity of WNV outbreaks have increased 
significantly in recent years, with a higher incidence of neuroinvasive infections, marking 2012 
as one of the deadliest (286 fatalities) on record [1]. Currently, no vaccine or therapeutic agent 
has been approved for human use. The global threat of WNV epidemics and the lack of 
treatment warrant the development of vaccines and production platforms that can bring products 
to market at low cost. 
2. WNV vaccine development and current vaccine candidates 
Studies have shown that neutralizing humoral response is critical for protective immunity against 
WNV and is a potential correlate of vaccine-induced protection [10]. To maximize the induction 
of protective antibodies, several different types of vaccine candidates against WNV are being 
developed, including candidates based on inactivated, live-attenuated, or chimeric virus, viral 
DNA, and WNV protein subunits. While some of these vaccines are available for use in animals 
and have been evaluated in clinical trials (Table 1), a licensed human vaccine remains elusive. 
2.1 Inactivated WNV  vaccines  
Two inactivated whole WNV vaccines have been approved for veterinary use. The first 
inactivated vaccine (WN-Innovator) is based on whole NY99, a North American highly virulent 
WNV strain. It requires two doses and an annual booster shot, and can offer protection from 
fatal neuroinvasive disease in horses and hamsters [11, 12]. Baboons immunized with the same 
vaccine also showed strong IgG and IgM responses and exhibited low viremia upon challenge 
[13]. Similarly, other inactivated virus vaccine candidates have shown protection against lethal 
WNV challenges in geese and mice, respectively [14]. Recently, a hydrogen peroxide-
inactivated KUN virus candidate was shown to protect mice against lethal challenge of NY99 
strain [15]. One potential issue of using inactivated virus as vaccines is the generation of viral 
sequence variants during processing of parent virus stocks. To minimize such risk, a cDNA 
clone of NY99 was synthesized to produce the RNA viral genome. The inactivated WNV derived 
from the synthetic genome was shown to elicit strong protection in mice following two doses 
delivery [16]. While successful in eliciting protective immunity, inactivated whole WNV as human 
vaccines will face safety concerns and the corresponding regulatory hurdles.  
2.2 Live-attenuated WNV vaccines  
Live-attenuated WNV vaccines based on naturally attenuated strains or infectious clones have 
been developed to enhance the induction of immune response to NS. Thus, this strategy may 
evoke cellular immune responses that contribute to clearance of subsequent virus infection. 
KUN shares all the neutralizing epitopes and 98% of its amino acid sequence with the WNV 
NY99, but causes far less severe infections [17]. When KUN is delivered into mice, a strong 
neutralizing antibody response against NY99 was detected in immunized animals. On a lethal 
dose challenge with NY99, 80-100% immunized mice were protected [17]. A naturally 
attenuated lineage 2 strain derived from an infectious clone (WN1415) has also been tested as 
a live vaccine candidate. The attenuation is due to a set of mutations in the genes of NS; this 
strain can elicit a robust immune response that protects mice from a lethal NY99 challenge [18]. 
Other live-attenuated vaccine candidates include strains with mutations at glycosylation sites of 
the E and NS1 proteins or at specific sites of the E protein that are associated with attenuation 
of JEV [19, 20]. These strains are highly attenuated in causing neuroinvasive diseases, but still 
can stimulate neutralizing humoral response that provides protection against WNV challenge 
[19, 20].  
2.3 Live-attenuated WNV chimeric vaccines 
The safety profile of other existing attenuated flavivirus vaccines can be exploited to develop 
chimeric vaccines that carry WNV antigens. For example, the attenuated chimeric vaccine 
commercialized for veterinary use (ChimerVax-VN01), was developed based on the parent YFV 
17D vaccine by replacing the prM and E genes of YFV with those of NY99 [21]. For human 
application, three mutations in the E protein responsible the attenuation of JEV SA14-14-2 
vaccine were introduced to further attenuate the chimeric virus (ChimerVax-VN02) [21]. The 
safety of this live chimeric vaccine was demonstrated in a Phase I clinical trial with healthy 
adults of 18-40 years old. Strong and durable (12 months) neutralizing antibodies were detected 
in all singly inoculated subjects (103 or 105 PFU per dose), and T-cell responses specific to the 
WNV E protein was also identified in 83-87% of vaccinated individuals [22]. The safety and 
immunogenicity of this chimeric vaccine was further demonstrated in two Phase II clinical trials 
in three adult age groups of 18-40, 41-64 and > 65 years old [23, 24]. Another example of 
chimeric vaccine is constructed by replacing DENV-4 prM and E genes with their equivalent 
genes of WNV. The WNV/DENV-4 chimeric viruses are highly attenuated, but are highly 
immunogenic in mice, geese and non-human primates [25]. Two Phase I clinical trials on 
healthy adults (18-50 years old) have been recently completed and the results indicated that the 
candidate was well tolerated and immunogenic. Specifically, seroconversion to WNV NY99 was 
observed in 74% (10³ PFU), 75% (10⁴ PFU), and 55% (10⁵ PFU) of subjects after a single dose, 
and a second 10⁵ PFU dose given 6 months after the first dose increased the seroconversion 
rate to 89% [26]. Since this vaccine is attenuated by a dual-strategy mechanism, i.e. 
chimerization of WNV with a non-neuroinvasive flavivirus, DENV-4, and a 30-nucleotide deletion 
in the 3′ UTR, this makes reversion to a wild-type WNV or DENV within a vaccinated host very 
unlikely [25]. However, because this chimeric virus can be transmitted by a known vector 
mosquito (Aedes albopictus) for both WNV and DENV [27], potential safety issues have to be 
addressed for its further development.   
2.4 Vectored virus and DNA WNV vaccines  
Since vectored viruses that are commonly used to express heterologous antigens replicate 
poorly in mammalian cells, vaccines based on these vectors often have superior safety profiles 
than live-attenuated vaccines. Importantly, these vectors can induce strong humoral and cell-
mediated immune responses due to the robust expression of antigens and the process of 
abortive replication, which mimics a natural viral infection. For example, a canarypox viral vector 
that expresses the WNV prM and E proteins has been shown to elicit protective immunity in 
several animal species and has been approved for veterinary use [11]. A WNV E protein-
expressing vesicular stomatitis virus vector also induced cell-mediated responses and protected 
mice from a lethal challenge of WNV [28]. Other examples include WNV-E expressing lentiviral 
vectors, which, in a single dose, fully protected mice from a lethal WNV challenge [29].  
DNA-based WNV Innovator vaccine encodes genes for the coexpression of the WNV prM and E 
proteins (prM-E), which facilitates the formation of virus-like particles (VLPs) in host cells, and 
induce protective immunity in horses, mice and several bird species [30]. A similar DNA vaccine 
was tested in Phase I clinical trials, demonstrating its ability to induce neutralizing antibodies 
and CD4+ and/or CD8+ T-cell responses specific to WNV M or E proteins [31]. Other DNA 
vaccine candidates include constructs that coexpress the domain III (DIII) of the WNV E protein 
and interleukin-15 (IL-15) to enhance humoral immunity, and that expresses a fusion protein of 
prM-E with lysosome-associated membrane protein to improve MHC-II presentation and 
neutralizing antibody response [32].  An interesting variation of this strategy is to express a CP-
deleted WNV or KUN subgenome with the expression of CP supplied in trans. This design 
allows the production of a “single round infectious particles.” The single-cycle pseudoinfectious 
virions replicate once and express WNV antigens to generate VLPs in host cells, which mimic 
live viral infection and, therefore, greatly enhance their immunogenicity and protection against 
WNV challenges in small animal and non-human primate models [33].  
2.5 Subunit WNV vaccines        
The search for safer vaccines has driven the development of vaccines based on WNV protein 
subunits. The WNV E protein has been shown to be essential for virus attachment and 
subsequent entry into host cells, and contains the majority of protective epitopes for neutralizing 
antibodies [10]. Crystal structure analysis revealed the three domain architecture of the E 
protein: a central β-barrel domain I (DI), an elongated domain II (DII) containing the fusion loop 
conserved in all flaviviruses, and a C-terminal DIII with an immunoglobulin-like fold [4]. It was 
found that antibody response to different domains of the E protein has different properties in 
neutralization, cross-reactivity, and maturation sensitivity. For example, weakly or non-
neutralizing antibodies induced by WNV in humans are typically against the epitopes on the 
fusion loop of DII [34]. These antibodies are also cross-reactive amongst flaviviruses and can 
neutralize the partially but not fully matured WNV [35]. In contrast, epitopes for the most potently 
neutralizing antibodies are localized in DIII [36]. These neutralizing antibodies are WNV and 
often genotype specific, and can equivalently neutralize immature and fully matured WNV [35].    
E protein has been examined as the prime candidate of subunit vaccines against WNV. For 
example, an insect cell-produced E protein offered protection against WNV challenge in mice, 
hamsters, chickens, geese and rhesus monkeys; and it was well tolerated and induced a 
neutralizing antibody response in all immunized human subjects [37]. A recent study showed 
that E protein can also elicit durable and TH1/Th2 balanced humoral and cellular immune 
responses against both lineage 1 and 2 WNV when a saponin-based adjuvant is used [38]. E 
DIII has also been explored as a target for developing WMV subunit vaccines. For example, E. 
coli and insect cell-produced DIII conferred protection against a lethal WNV challenge in mice 
[39].  
Coexpression of prM and E often leads to the assembly of VLPs that share many immunogenic 
properties with the native WNV [40].  Insect cell-produced prM-E VLPs were shown to protect 
mice from lethal WNV challenge and induced sterilizing immunity [41].  A single inoculation of 
mammalian cell-derived lineage 1 WNV prM-E VLPs also protected mice against a lethal 
challenge with both lineage 1 and 2 WNV, demonstrating that VLP-based vaccines are more 
immunogenic than those based-on individual subunit antigens [42].  
3. WNV vaccine candidates produced in plants 
3.1 Plants as a production system for WNV vaccines 
Despite the development of aforementioned vaccine candidates, the eventual approval and 
commercialization of human vaccines against WNV may largely depend on the economics of 
vaccine production and implementation of a vaccination program. Studies have shown that a 
universal WNV vaccination program produced under current vaccine platforms would not be 
cost effective compared with that of post-exposure treatment [43]. Another analysis indicated 
that vaccines based on technologies with lower production costs are needed because only they 
could outcompete the costs associated with surveillance and treatment [44]. Because plants can 
produce large quantities of recombinant proteins at low cost, plant-based systems may provide 
solutions to overcome the economic challenge of WNV vaccine production [45]. Plant biomass 
generation does not require prohibitive capital investment for building fermentation facilities and 
there is no need to construct duplicate facilities for scale-up operation [46]. As a result, 
upstream processing in plant-based systems can be operated and scaled-up in a flexible and 
cost-efficient manner that cannot be easily matched by fermentation-based technologies 
currently used for vaccine production [47, 48].   
Systems based on transgenic plants were first explored to produce subunit vaccines for 
flavivirus. For example, the JEV E protein accumulated to a low level of 1.1–1.9 μg/mg of total 
soluble protein in transgenic rice leaves; and E-containing leaf extracts induced an E-specific 
neutralizing antibody response in mice with similar titers as that induced by an E. coli-produced 
E antigen [49]. The issue of low vaccine accumulation in early transgenic systems has been 
overcome by using improved promoters [45, 50]. The development of transient expression 
systems based on plant viruses provides another alternative platform for vaccine production. 
These transient expression systems drive high-level accumulation of pharmaceutical protein 
within 1 to 2 weeks of vector delivery [51-58]. The speed and high-yield benefits of the transient 
system offer the plant-expression system the versatility to quickly produce subunit vaccines 
against viruses such as WNV that have multiple lineages with unpredictable outbreaks in 
various parts of the world.  
3.2 Plant-produced subunit vaccines against WNV   
As DIII of WNV E contains the majority of the neutralizing epitopes that induce strong host 
antibody responses and/or protective immunity against WNV, we explored the possibility of 
producing DIII in plants [59, 60]. The coding sequence of DIII was cloned into the expression 
cassette in a deconstructed viral expression vector and delivered into lettuce (with geminiviral 
vector) or Nicotiana benthamiana (with TMV-based MagnICON vector) plants through 
agroinfiltration [61, 62] for accumulation in ER, cytosol and chloroplast. Western blot analysis 
detected DIII antigen in plant samples that were infiltrated with DIII construct with the expected 
molecular weight. It appeared that DIII was stable during expression and isolation, as only the 
full-length DIII was observed [59]. Further ELISA analysis confirmed the expression of DIII in 
plants and indicated that DIII was produced quickly in plants and reached the highest 
accumulation level within 4 days post infiltration (DPI) with an average level of 100 g/g leaf 
fresh weight (LFW) [59]. This level of expression is higher than DENV DIII expression with a 
similar vector system and presents the highest level of accumulation ever reported in plants at 
that time [59, 63]. Detailed analysis indicated that the expression level of DIII in plant tissue is 
affected by the particular subcellular compartment where DIII accumulates. For example, if DIII 
was targeted to the cytosol or chloroplast, the maximal levels of accumulation are below 1.16 
g/g LFW, approximately 86 times less than that in ER [59]. The overall DIII expression levels in 
plants is lower than that of other vaccine candidates we have produced using the MagnICON 
vectors [52]. Since leaf necrosis was observed in DIII-construct infiltrated plants, DIII may be 
toxic to plant cells that may shorten the window of its accumulation, contributing to the lower 
expression level. Because DIII was produced under standard conditions, its expression could be 
further enhanced by genetic manipulations of the DIII gene and the plant host [45].  
Plant-derived DIII was further examined for its structural and immunological properties. We first 
tested its ability in binding E16, a MAb that neutralizes WNV potently and protects mice against 
a lethal infection of WNV in both prophylactic and post-exposure models [64-66]. ELISA showed 
that plant DIII specially bound to E16. The epitope for E16 consists of four discontinuous 
regions of DIII, thus, the results demonstrate that plant-produced DIII was folded into a tertiary 
structure similar to that of the native viral DIII. The immunogenicity of plant DIII was evaluated in 
mice with four doses of 5 g or 25 g DIII injected subcutaneously with alum as adjuvant. WNV 
E DIII-specific IgG was detected after the first dose in all mice immunized with 25 g of plant-
produced DIII, while the 5 g dosage induced a response after the third DIII injection (Figure. 
1). Results also demonstrated that plant-derived DIII elicited at least equivalent anti-DIII IgG 
titers as those of E. coli-produced DIII (P >0.5) [59]. This result is in contrast to the low titers 
induced by a plant-produced DENV DIII even when the TiterMax Gold was used as adjuvant 
[63]. Further analysis of IgG subtypes indicated that > 99% of DIII-specific IgG was the IgG1 
subtype, suggesting an overwhelmingly Th2-type response [59]. A previous study reported that 
E. coli-produced DIII with CpG adjuvant induced a Th1-biased response [39]. This inconsistency 
is not surprising, as studies have shown that flavivirus antigens tend to stimulate a Th2 type 
response when alum is used as the adjuvant, while CpG is likely to skew the response toward 
the Th1 type [67]. Flow cytometry analysis of antisera from plant-DIII immunized mice showed 
that they contain antibodies that can recognize DIII in its native conformation (Figure. 2) and 
possibly bind to the same protective epitope as E16 [59].  
To overcome the relative low level expression of DIII in plants, we examined the accumulation 
of the WNV E protein. It was shown that including DI and DII of the E protein greatly reduced 
leaf necrosis and, hence, increased the subunit protein expression level from 100 g/g LFW to > 
600 g/g LFW (Chen, manuscript in preparation). To avoid the potential adverse effect derived 
from the plant-specific glycosylation pattern on E protein, we also used a glycol-engineered 
plant line and yielded E protein with full mammalian glycoforms [66]. Furthermore, our data also 
showed that plant-derived E protein can be easily purified to homogeneity with a similar 
procedure as for DIII from plants, and immunization with alum as adjuvant in mice induced 
robust neutralizing antibody responses specific for both WNV E and DIII, skewing towards Th2 
type in both IgG subtypes and cytokine profiles (Chen, manuscript in preparation). These results 
are consistent with the observation that JEV E protein can be successfully expressed alone, 
without prM in plants, in contrast to animal cells where prM is necessary for the proper 
expressing and folding of the JEV E protein [68].  
3.3 VLP-based WNV vaccines produced in plants  
Since VLPs mimic the architecture of infectious viruses but lack the viral genome, they often 
elicit more potent cellular and humoral immune responses without adjuvants than other 
recombinant antigens and present a safer vaccine alternative than attenuated or inactivated 
viruses [69]. As WNV is a virus surrounded with a lipid membrane, enveloped VLPs are 
produced when prM and E protein are co-expressed in insect and mammalian cells, which have 
been shown to induce more potent immune response than E protein alone and are being 
investigated in clinical trials [40-42] The feasibility of using plants to produce enveloped VLPs as 
vaccines against WNV was explored. When the NY99 prM-E construct was coexpressed in 
plants, prM and E protein were both detected at the expected sizes by western blot analysis 
(Figure 3). In addition, a positive band corresponding to the size of the processed mature 
membrane (M) protein was also detected by anti-WNV M-E antibodies with the relative band 
intensity of prM and M (Figure 3) comparable to that in the purified WNV virion [70]. This 
suggests that WNV prM to M processing was similar between plant-derived recombinant 
antigen and virion protein. Results of sucrose gradient centrifugation confirmed the assembly of 
VLPs containing both E and prM/M proteins of WNV [69]. The immunogenicity of plant-derived 
WNV enveloped VLPs are being evaluated in mice.  
For many viruses, VLPs assembled from CPs have also been shown to trigger strong protective 
immune responses at very low doses even in the absence of adjuvants [71]. Like native non-
enveloped viruses, their quasi-crystalline surface with arrays of repetitive epitopes is the prime 
target for B cell recognition and can efficiently crosslink epitope-specific immunoglobulins (Ig) on 
B cells inducing strong B cell responses [72]. The particulate nature and high-density 
presentation of CP on their surface make VLPs an attractive carrier for displaying foreign 
epitopes. The immunogenicity of displayed heterologous antigen is enhanced through multiple 
potential mechanisms as it is anchored in the VLP and presented in a high-density repetitive 
array, thereby, enhancing immune cell uptake and stimulation. To develop a CP-based VLP 
vaccine against WNV, we first fused the coding sequence of DIII of WNV E to the 3’ end of 
hepatitis B core antigen (HBcAg) gene, aiming to create an HBcAg-DIII chimeric VLP that 
displays the DIII epitopes on its surface. Expression of this construct in N. benthamiana 
rendered robust production of the HBcAg-DIII fusion antigen at the expected molecular size 
(~27kDa) in plant leaves, as verified by western blot analysis with both anti-HBcAg and anti-
WNV DIII antibodies (Figure 4A). Further analysis revealed that high-level (~ 350 g/g LFW) 
accumulation of this fusion protein was achieved within 6 DPI through transient expression 
(Figure 4B). Analyses with sucrose gradient centrifugation and electron microscopy confirmed 
the assembly of the chimeric VLPs (Figure 4C). Competitive ELISA indicated that HBcAg-DIII 
effectively competed with soluble DIII in binding to an anti-DIII MAb E16, confirming that DIII 
was displayed on the surface of the chimeric VLPs [58].  Furthermore, immunization of mice 
with a single dose (25 g) of these chimeric VLPs induced strong DIII-specific B and T-cell 
responses that are superior to that of the non-fused DIII antigen. We also explored the 
expression of HBcAg-DIII with MagnICON vectors. This led to even higher levels accumulation 
(> 1,000 g/g LFW) of HBcAg-DIII VLPs that have similar structural and immunological 
properties as those obtained by geminiviral vectors. 
3.4 Downstream processing of plant-derived vaccines against WNV  
The lack of scalable downstream processing procedures, the uncertainty of regulatory 
compliance for production processes, and the lack of demonstration to date of plant-derived 
vaccines that meet the required safety standards of regulatory agencies are some of the major 
challenges to the commercialization of plant-made vaccines [45, 46, 73]. To overcome these 
challenges, we have developed a novel processing scheme for recovering VLPs from plant 
tissue and through it, successfully demonstrated the feasibility of operating the upstream and 
downstream production processes under the US Food and Drug Administration (FDA) current 
Good Manufacture Practice (cGMP) regulations, producing high quality VLPs that meet all 
preset release specifications in identity, purity, potency and safety [74].  Such a first precedent 
of producing vaccine candidates under FDA regulations in an academic setting is an important 
step towards the commercialization of plant-derived vaccines. This scalable downstream 
process also allowed us to extract and purify HBcAg-DIII VLPs to homogeneity [58]. It not only 
effectively separated the chimeric VLPs from other leaf components, but also preserved the 
structural integrity of the fusion particle to yield assembled VLPs with consistent size (Figure 
4C). Similarly, a robust downstream processing procedure for recovering and purifying prM-E 
enveloped VLPs from N. benthamiana has also been established. It consists of leaf 
homogenization, clarification of extract by centrifugation, and purification by a series of 
chromatographic steps including ion-exchange and affinity chromatography similar to that for 
processing VLP vaccines against influenza [75]. Collectively, these results demonstrate the 
robustness of the plant transient expression system and the availability of scalable downstream 
schemes, which will facilitate the broad application of plants as hosts for the development and 
production of vaccines against WNV.  
4. Conclusions 
The expanding epidemics of WNV around the world demand the development of effective 
vaccines and production platforms that can quickly transfer the vaccine candidates into the 
clinical setting at low cost. The results reviewed here demonstrate that plants provide a viable 
alternative system for the production of subunit vaccines against WNV that can potentially meet 
these needs. Specifically, the expression of major human WNV vaccine candidates that are 
being tested in clinical trials based on the E protein, its DIII fragment, or prM-E VLPs have all 
been successfully demonstrated in plants. Chimeric VLPs that display DIII on its surface have 
also been produced. Transient expression based on deconstructed viral vectors has allowed the 
high level accumulation of these vaccine candidates. Furthermore, a simple, scalable and 
cGMP compliant downstream processing scheme has also been developed to effectively 
recover and purify these vaccine candidates from plants. The potency for some of these vaccine 
candidates has been demonstrated in mice, which is at least equivalent to subunit-based 
candidates produced by other production systems. With the demonstrated unmatchable 
flexibility and cost-efficiency in the upstream processing of plant-based systems [48], these 
results indicate that plants can produce WNV vaccines with comparable potency as other 
production platforms but with much lower cost. Remaining challenges for WNV vaccine 
development include the need to address safety and efficacy concerns for the “at risk” 
populations of elderly and immune-comprised individuals and the potential risk of ADE. Plants 
may play an important role in overcoming these challenges. For example, the recent 
development of glycoengineered plants would facilitate the understanding of carbohydrate 
moiety’s function in inducing ADE by antibodies [65, 76], which would guide future vaccine 
design. A lingering skepticism of plant-based manufacturing systems has been the absence of 
approved human products in the US [77]. This barrier has finally been overcome by the FDA 
approval of a plant-produced glucocerebrosidase for treating Gaucher disease [69]. In a 
remarkable unprecedented and exciting development, an experimental cocktail of three plant-
made MAbs was recently used to treat several Ebola patients, showing promising results [78]. 
We speculate that plant-based systems will offer a more favorable cost/benefit ratio for WNV 
vaccination programs and encourage the eventual licensure and commercial production of 
human vaccines against WNV.  
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7. Figure legends 
Figure 1. DIII-specific antibody responses in mice upon subcutaneous delivery of plant-derived 
DIII. BALB/C mice (n = 6 per group) were injected on weeks 0, 3, 6 and 9 with the indicated 
dosage of antigen. Blood samples were collected on the indicated weeks and serum IgG was 
measured by ELISA. The y axis shows the geometric means titers (GMT) and the error bars 
show the 95% level of confidence of the mean [59].  
Figure 2. Recognition of antibodies in sera to DIII displayed on yeast cell surface. DIII-
displaying yeast cells were incubated with pooled sera collected on week 11 from mice injected 
with either 25 g of plant-produced DIII (A) or PBS (B) with hE16 as the positive control MAb 
(C). Yeast cells were subsequently stained with an Alexa Fluor 488-conjugated goat anti-mouse 
(A and B) or goat anti-human (C) secondary antibody and processed by flow cytometry [59]. 
Figure 3. Production of enveloped VLPs based on WNV prM-E protein in N. benthamiana 
plants. Leaf tissue was infiltrated with the WNV prM-E construct. PrM-E VLPs were extracted 
from leaves and isolated by PEG precipitation. Samples were separated on 4-12% SDS-PAGE 
gels and blotted onto PVDF membranes for western blot analysis with an anti-WNV E antibody 
(Lanes 1-3) or an anti-WNV M-E antibody (Lane 4). Lane1: Sample from buffer-infiltrated 
leaves, Lane 2: Purified WNV E protein as positive control, Lanes 3-4: Samples from leaves 
infiltrated with the prM-E construct. * : E protein; **: prM protein;  ***: Processed M protein [69].  
Figure 4. Plant-derived chimeric HBcAg-WNV DIII VLPs. (A) Western blot analysis. Chimeric 
VLPs were extracted from HBcAg-WNV DIII construct-infiltrated N. benthamiana leaves, purified 
and separated on 10% SDS-PAGE gels. Proteins were transferred onto PVDF membranes 
which were subsequently incubated with an anti-HBcAg antibody or an anti-WNV DIII antibody. 
Lane1: Proteins extracted from HBcAg-DIII construct-infiltrated leaves, Lane 2: Equivalent 
proteins from un-infiltrated leaves. (B) Temporal expression pattern of HBcAg-WNV DIII. Leaf 
proteins were extracted from infiltrated leaves 3 to 7 DPI and analyzed with a sandwich ELISA 
that detects HBcAg. Mean ± standard error (SEM) of samples from three independent infiltration 
experiments are presented. (C) Electron microscopy of chimeric HBcAg-WNV DIII VLPs. 
HBcAg-DIII chimeric VLPs were purified from infiltrated leaves, stained with 0.2% aqueous 
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Table 1. West Nile virus vaccines licensed for veterinary use or in human clinical trials  
 
NR: Not reported; NIAID: The National Institute of Allergy and Infectious Diseases.  
 
Antigen Development Stage Seroconversion rate     Sponsor References 
Whole inactivated WNV Licensed for veterinary use 100% in horses Fort Dodge Animal Health  [12] 
Whole inactivated WNV Licensed for veterinary use NR Boehringer Ingelheim NR 
Canarypox expressing WNV prM-E Licensed for veterinary use 100% in horses Merial-Sanofi  [11] 
YFV17D backbone expressing WNV prM-E Licensed for veterinary use (Recalled in 2010) 100% in horses Intervet [11] 
Plasmid DNA expressing WNV prM-E Licensed for veterinary use (Discontinued) 100% in horses Fort Dodge Animal Health [30] 
DENV-4 backbone expressing WNV prM-E Phase I 75-89% NIAID [26] 
YFV17D backbone expressing WNV prM-E Phase I 100% Sanofi [22] 
YFV17D backbone expressing WNV prM-E Phase II 95.4-97.3% Sanofi [23, 24] 
Soluble WNV E protein Phase I 100% Hawaii Biotech [37] 
Plasmid DNA expressing WNV prM-E Phase I 96.6-100% Vical-NIAID [31, 79] 
